Outcome of Board Meeting May 25, 2026
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare Solutions reported audited FY26 results with consolidated revenue of Rs. 65,912 million (up 28% YoY from Rs. 51,353 million) and consolidated PAT of Rs. 1,458 million (up 36% YoY from Rs. 1,074 million). The Board approved re-appointment of 3 Independent Directors (Sujesh Vasudevan, Rajesh Shashikant Dalal, and Sandhya Gadkari Sharma) for a second 5-year term from August 2026, subject to shareholder approval at the 8th AGM on August 19, 2026. The company allotted 7,240 equity shares upon exercise of vested ESOPs and granted fresh 7,300 options under the Entero Employee Stock Option Plan 2023. The Board also approved acquisition of Vishal Surgicals and Vishal Surgicals & Medicals (a partnership firm) through subsidiary Sai Pharma Distributors Private Limited via Slump Sale/Business Transfer Agreement. Auditors gave an unmodified opinion on the financial results.
Strong financial performance with 28% revenue growth and 36% PAT growth demonstrates healthy expansion. ESOP activities indicate retention and alignment of employee interests. The acquisition expands the pharma distribution network. Positive signals for shareholders with consistent profitability and governance updates.